Form 4: Halozyme Therapeutics Director Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Jeffrey William Henderson, a director at Halozyme Therapeutics, sold 503 shares of common stock at $64.05 per share on April 1, 2025, under a pre-arranged trading plan.
Summary
- On April 1, 2025, Jeffrey William Henderson, a director at Halozyme Therapeutics, sold 503 shares of common stock.
- The sale was executed at a price of $64.05 per share.
- Following the transaction, Henderson directly owns 33,108 shares of Halozyme Therapeutics.
- The sale was conducted under a pre-arranged trading plan adopted on September 17, 2024, in accordance with Rule 10b5-1.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook.
Industry Context
Sales by insiders are a normal part of corporate governance. The use of a 10b5-1 plan indicates the insider is selling shares at predetermined times and prices to avoid accusations of insider trading.
Stakeholder Impact
- The sale of shares by a director could have a minor impact on shareholder confidence, but the existence of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 2024-09-17 | Date the Reporting Person adopted a written trading plan in accordance with Rule 10b5-1. |
| 2025-04-01 | Date of the transaction: sale of 503 shares of common stock. |
Keywords
Halozyme Therapeutics, Director, Share Sale, Form 4, 10b5-1 Plan, Equity Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.